Peritoneal mesothelioma is an aggressive form of cancer caused by asbestos exposure. While it is a rare form of cancer, it can be deadly if left untreated. Recently, a new research study has shed light on peritoneal mesothelioma, providing new insight into the disease and the treatments available.
The research was conducted by a team of scientists from the University of North Carolina at Chapel Hill. The study focused on a new kind of treatment known as hyperthermic intraperitoneal chemotherapy, or HIPEC. The researchers found that this treatment can be effective in treating peritoneal mesothelioma, providing hope for those who suffer from this disease.
HIPEC involves the insertion of heated chemotherapy drugs directly into the abdomen. This allows the drugs to stay in the area for a longer period of time, increasing their effectiveness at killing cancer cells. The researchers found that HIPEC was more effective than traditional chemotherapy treatments, resulting in higher survival rates for those with peritoneal mesothelioma.
The study also revealed that the combination of chemotherapy drugs used in HIPEC can vary depending on the individual patient. This means that doctors can tailor the treatment to each patient, increasing its effectiveness.
The research also showed that patients who received HIPEC were more likely to survive longer than those who received traditional chemotherapy treatments. The researchers found that the average survival rate for those who underwent HIPEC was 28 months, compared to 17 months for those who received chemotherapy alone.
The study provides new hope for those with peritoneal mesothelioma. It shows that there are effective treatments available, and that the disease can be managed with the right combination of drugs. While more research is needed to understand how to best use HIPEC in treating peritoneal mesothelioma, this study provides hope for the future.